The American Society of Gene & Cell Therapy

Analysis

The American Society of Gene & Cell Therapy is a registered charity in United States, based in Waukesha, WI. It received its IRS tax-exemption ruling in April 1997, 29 years ago. Its declared purposes cover medical research, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, The American Society of Gene & Cell Therapy reported income of $16.4m and spending of $13.8m, spending 84% of its income. Across the 5 years on record, from December 2019 to December 2023, income grew from $6.5m to $16.4m (+151%), an average of +26% a year. The sharpest change came in the year to December 2022, when income rose by 40%. Over the whole period it spent 79% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, The American Society of Gene & Cell Therapy sits at the 87th percentile: it is larger than about 87% of them. Against every charity in United States with reported income it ranks in the 97th percentile, and in the 97th percentile within WI. Charities of a similar size with the same main cause include Virginia League for Planned Parenthood Inc ($16.4m), Waimanalo Health Center ($16.4m) and Deborah Hospital Foundation ($16.3m).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 6.4% and program service revenue 89% of the total. Compensation of current officers, directors and key employees was $469k (3.4% of expenses). Other salaries and wages came to $3.2m. At year end it held assets of $23.8m against liabilities of $6.6m, net assets of $17.2m. It reported 45 employees.